Form 4: BIO-TECHNE Director Boosts Stake with Stock & Options
Insider Transaction Report
BIO-TECHNE Director Robert V. Baumgartner acquired 1,640 shares of common stock and 3,777 stock options on October 30, 2025.
Summary
- Robert V. Baumgartner, a Director of BIO-TECHNE Corp (TECH), reported an acquisition of securities.
- On October 30, 2025, Mr. Baumgartner acquired 1,640 shares of common stock at a price of $0 per share, likely as a grant.
- Following this transaction, Mr. Baumgartner beneficially owns 46,503 shares of common stock directly.
- Additionally, on October 30, 2025, Mr. Baumgartner acquired 3,777 stock options with an exercise price of $60.96.
- These newly acquired options have an expiration date of October 30, 2035, and will vest on the earlier of the one-year anniversary of the grant date (October 30, 2026) or the date of Bio-Techne's 2026 annual meeting of shareholders.
- Mr. Baumgartner now holds a total of 67,321 stock options from various grants, with exercise prices ranging from $25.30 to $128.81 and expiration dates extending to October 30, 2035.
Sentiment
Score: 7
Explanation: The acquisition of additional common stock and stock options by a director is generally viewed as a positive signal, indicating management's continued confidence in the company's future prospects and aligning their interests with shareholders.
Positives
- A director acquiring additional common stock and stock options signals confidence in the company's future performance and strategic direction.
- The acquisition of shares at $0 indicates a grant, which is a common form of executive compensation aligning management interests with shareholders.
Future Outlook
The filing does not provide specific forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider transaction.
Industry Context
This Form 4 filing reports a routine insider transaction, specifically an equity grant to a director. Such grants are common practice across various industries to align executive incentives with shareholder value. It does not provide broader industry trends or competitive analysis.
Related Party Transactions
- The acquisition of 1,640 shares of common stock and 3,777 stock options by Director Robert V. Baumgartner constitutes a related party transaction, as it involves an equity grant from the company to a member of its board.
Stakeholder Impact
- Shareholders may view this transaction positively, as it demonstrates a director's increased vested interest in the company's long-term success, potentially signaling confidence in future stock performance.
Next Steps
- The newly acquired stock options will vest on the earlier of October 30, 2026, or the date of Bio-Techne's 2026 annual meeting of shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/26/2017 | Date exercisable for 15,940 stock options with an exercise price of $25.30. |
| 10/25/2018 | Date exercisable for 12,500 stock options with an exercise price of $31.26. |
| 10/24/2019 | Date exercisable for 7,592 stock options with an exercise price of $44.96. |
| 10/24/2020 | Date exercisable for 8,044 stock options with an exercise price of $50.41. |
| 10/28/2021 | Date exercisable for 6,028 stock options with an exercise price of $63.92. |
| 10/27/2022 | Date exercisable for 2,532 stock options with an exercise price of $128.81. |
| 10/26/2023 | Date exercisable for 3,460 stock options with an exercise price of $73.94. |
| 10/24/2024 | Date exercisable for 3,937 stock options with an exercise price of $61.51. |
| 10/24/2025 | Date exercisable for 3,511 stock options with an exercise price of $68.37. |
| 10/30/2025 | Date of earliest transaction, involving the acquisition of common stock and new stock options. |
| 11/03/2025 | Signature date of the reporting person's attorney-in-fact. |
| 10/26/2026 | Expiration date for 15,940 stock options granted in 2017. Also, the one-year anniversary of the grant date for the newly acquired options, which is a vesting condition. |
| 10/26/2027 | Expiration date for 12,500 stock options granted in 2018. |
| 10/25/2028 | Expiration date for 7,592 stock options granted in 2019. |
| 10/24/2029 | Expiration date for 8,044 stock options granted in 2020. |
| 10/29/2030 | Expiration date for 6,028 stock options granted in 2021. |
| 10/28/2031 | Expiration date for 2,532 stock options granted in 2022. |
| 10/27/2032 | Expiration date for 3,460 stock options granted in 2023. |
| 10/26/2033 | Expiration date for 3,937 stock options granted in 2024. |
| 10/24/2034 | Expiration date for 3,511 stock options granted in 2025 (prior to this filing). |
| 10/30/2035 | Expiration date for the newly acquired 3,777 stock options. |
Recommendation
holdWhile insider buying, especially through grants, is a positive indicator of management confidence, this Form 4 reports a routine compensation event rather than a significant open-market purchase. It reinforces a 'hold' position by confirming alignment of interests, but does not present new fundamental information warranting an immediate 'buy' or 'sell' without further analysis of the company's financial performance and market conditions.
Keywords
BIO-TECHNE, TECH, Form 4, Insider Transaction, Stock Options, Director, Equity Grant, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.